Global sportswear giant Nike has announced a major leadership change, naming former Pfizer finance chief David Denton as its new Executive Vice President and Chief Financial Officer, effective August 17, 2026. The move comes as CEO Elliott Hill continues to reshape the company’s leadership team and accelerate Nike’s long-term turnaround strategy.
Denton will succeed longtime Nike executive Matthew Friend, who has spent nearly two decades with the company and served as CFO since 2020. Friend will remain with Nike through September 4 to ensure a smooth transition and will participate in the company’s fourth-quarter fiscal 2026 earnings call on June 30.
The appointment surprised many Wall Street analysts, particularly because it comes just days before Nike’s earnings announcement and because the company opted for an external hire rather than promoting from within. Analysts, however, largely view the move as a sign that Hill’s turnaround plan is entering a new phase. Jefferies described the change as “another tangible signal” that Nike’s recovery strategy is progressing in a measured and deliberate manner.
Experienced Finance Leader Joins Nike
Denton brings more than 30 years of finance and operational leadership experience. Before joining Nike, he served as CFO of Pfizer since 2022 and previously held senior finance roles at Lowe’s and CVS Health. His background includes overseeing large-scale transformations, capital allocation programs, and growth initiatives across major public companies.
In announcing the appointment, Hill said Denton’s experience, discipline, and operational rigor would help Nike execute its priorities consistently while supporting long-term value creation. Denton, meanwhile, described Nike as one of the world’s great brands and said he was excited to help the company invest strategically and drive sustainable growth.
Turnaround Still a Work in Progress
The CFO transition comes as Nike continues to navigate a challenging recovery. Since returning as CEO in October 2024, Hill has focused on reconnecting the brand with its athletic roots, rebuilding wholesale partnerships, improving product innovation, and streamlining operations. The company has also undertaken significant leadership changes across marketing, product, and innovation functions.
Despite progress, Nike has faced persistent headwinds, including elevated inventories, softer consumer demand, and weakness in key markets such as China and North America. Earlier this year, executives acknowledged that the turnaround was progressing more slowly than originally anticipated. Nike has projected fourth-quarter revenue to decline between 2% and 4%, although upcoming results will receive a one-time boost from tariff refunds not included in prior guidance.
Analysts note that Denton’s lack of direct sportswear experience may create a learning curve, but his track record leading finance functions at Pfizer, Lowe’s, and CVS Health provides strong credentials for managing Nike’s complex global business.
The appointment of Denton represents one of the most significant executive moves since Hill’s return to Nike. As the company prepares its fiscal 2027 plans and seeks to restore growth momentum, investors will be watching closely to see whether the new finance chief can help strengthen execution, improve profitability, and support Nike’s next stage of recovery. For now, the leadership transition is being viewed less as a reaction to immediate challenges and more as a strategic step toward building a stronger long-term foundation.
